New Congressional Bill Could Boost Development Of Plant-Based Medicines, Including Those Derived From Cannabis Or Psychedelics
“The purpose is to turn up the heat and get resources to develop these more natural options that could be very important.” By Jack Gorsline, Psychedelic State(s) of America As cannabis rescheduling efforts under the Trump administration draw closer to finalization and Food and Drug Administration (FDA) approval of the first wave of synthetic psychedelic […]
How Cannabis Companies Can Take Advantage Of The Research And Development Tax Credit Under Federal Rescheduling (Op-Ed)
“Cannabis companies should consider various pitfalls to ensure not only legal compliance, but to maximize potential benefits.” By Meeren Amin, William Bogot and Douglas W. Charnas, Fox Rothschild LLP With rescheduling of medicinal marijuana and potential relief coming for recreational use, cannabis companies should be aware of tax benefits available to the industry. One such […]